Discovering biomarkers in high grade glioma to help find targeted treatments
Identifying the metabolic ‘Achilles Heel’ of childhood brain cancers
Developing a laboratory model of Wilms tumour to test potential new treatments
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies
Improving treatment and reducing side effects for children with B-cell NHL
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Developing better and safer medicines for children with leukaemia
Screening for novel drug combinations in childhood B-cell acute lymphoblastic leukaemia
Developing new treatments for high-risk neuroblastoma
Pre-clinical efficacy and biomarker studies of ALK, MAPK and MDM2-p53 inhibitor combinations in neuroblastoma
Improving our understanding of the genetics of neuroblastoma
Understanding neuroblastoma heterogeneity: genetic studies of circulating neuroblastoma tumour cells